APP and Alzheimer disease: Finally, we characterized differences in sleep–wake disturbances and microglial activation in 5xFAD and APP KI mice, and evaluated how the BACE1 inhibitor treatment differentially attenuated plaque load and sleep disturbances in the two AD mouse models.